Anzeige
Mehr »
Login
Mittwoch, 25.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

AFX News-Archiv vom 14.09.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
14.09.J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer1.062NEW BRUNSWICK (dpa-AFX) - Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, announced new data from the Phase 1b/2 OrigAMI-1 study, which showed amivantamab combined with chemotherapy...
► Artikel lesen
14.09.DIRECTV Reaches Agreement To Restore Disney Networks And Streaming Services886BURBANK (dpa-AFX) - DIRECTV and The Walt Disney Company have reached an agreement in principle for the distribution of Disney's linear networks and direct-to-consumer services, following a roughly...
► Artikel lesen
14.09.Pfizer: Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint1.191NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary...
► Artikel lesen
14.09.Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC750NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI (encorafenib)...
► Artikel lesen
14.09.J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial691NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that updated results from the Phase 3 MARIPOSA-2 study showed that combining RYBREVANT (amivantamab-vmjw) with chemotherapy provided...
► Artikel lesen